EA201890753A1 - Применение триентина для доставки меди в ишемизированную ткань - Google Patents

Применение триентина для доставки меди в ишемизированную ткань

Info

Publication number
EA201890753A1
EA201890753A1 EA201890753A EA201890753A EA201890753A1 EA 201890753 A1 EA201890753 A1 EA 201890753A1 EA 201890753 A EA201890753 A EA 201890753A EA 201890753 A EA201890753 A EA 201890753A EA 201890753 A1 EA201890753 A1 EA 201890753A1
Authority
EA
Eurasian Patent Office
Prior art keywords
copper
tissue
trientine
delivery
application
Prior art date
Application number
EA201890753A
Other languages
English (en)
Other versions
EA037045B1 (ru
Inventor
Юйцзянь Джеймс Кан
Original Assignee
Иннолайф Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иннолайф Ко., Лтд. filed Critical Иннолайф Ко., Лтд.
Publication of EA201890753A1 publication Critical patent/EA201890753A1/ru
Publication of EA037045B1 publication Critical patent/EA037045B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

В изобретении предлагаются способы восстановления и регенерации ишемизированной ткани путем промотирования перераспределения и повторного использования меди в ткани в результате введения композиции, включающей хелатирующий медь тетрамин, такой как триентин. В изобретении предлагаются способы и композиции для повышения внутриклеточного содержания меди и/или индуцирования восстановления ишемизированной ткани у индивидуума. Повышенное содержание меди в ишемизированной ткани может усиливать медьзависимую транскрипционную активность индуцируемого при гипоксии фактора 1 (HIF-1) и восстановление ткани.
EA201890753A 2015-09-24 2016-09-23 Применение триентина для доставки меди в ишемизированную ткань EA037045B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/090528 WO2017049529A1 (en) 2015-09-24 2015-09-24 A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
PCT/CN2016/099852 WO2017050271A1 (en) 2015-09-24 2016-09-23 Use of trientine to deliver copper to ischemic tissue

Publications (2)

Publication Number Publication Date
EA201890753A1 true EA201890753A1 (ru) 2018-08-31
EA037045B1 EA037045B1 (ru) 2021-01-29

Family

ID=58385664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890753A EA037045B1 (ru) 2015-09-24 2016-09-23 Применение триентина для доставки меди в ишемизированную ткань

Country Status (18)

Country Link
US (2) US11033579B2 (ru)
EP (1) EP3352743A4 (ru)
JP (1) JP7041053B2 (ru)
KR (1) KR20180055877A (ru)
CN (2) CN117338762A (ru)
AU (1) AU2016328156B2 (ru)
CA (1) CA2998958C (ru)
CL (1) CL2018000742A1 (ru)
CO (1) CO2018004189A2 (ru)
EA (1) EA037045B1 (ru)
EC (1) ECSP18031122A (ru)
HK (1) HK1259032A1 (ru)
IL (1) IL257904B (ru)
MX (1) MX2018003434A (ru)
NZ (1) NZ740728A (ru)
PE (1) PE20181166A1 (ru)
UA (1) UA123503C2 (ru)
WO (2) WO2017049529A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
CA3143523A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders
KR102508657B1 (ko) * 2021-02-17 2023-03-10 성균관대학교산학협력단 금-구리 나노입자를 유효성분으로 포함하는 허혈성 질환 예방 또는 치료용 조성물
AU2022231038A1 (en) * 2021-03-05 2023-09-21 Philera New Zealand Ltd. Treatment of copper disorders
CN115554473A (zh) * 2022-10-25 2023-01-03 华中科技大学同济医学院附属协和医院 去细胞心脏瓣膜复合材料及其制备方法和应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012221A (en) 1975-05-13 1977-03-15 International Copper Research Association Inc. Slow release copper toxicant compositions
US4952607A (en) 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
EP0145711A1 (en) 1983-06-10 1985-06-26 International Copper Association, Inc. Copper complex for treating cancer
PH21350A (en) 1984-06-04 1987-10-13 Smithkline Beckman Corp Tumor cell growth imhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes
US4550209A (en) 1984-07-26 1985-10-29 Texaco Inc. Process for the preparation of linear polyethylenepolyamines by reacting monoethanolamine with ethylenediamine in the presence of an intercalatively active catalyst
US5037812A (en) 1985-04-02 1991-08-06 Smithkline Beckman Corporation Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes
US4806517A (en) 1986-01-21 1989-02-21 Texaco Inc. Method for making pelleted phosphated catalysts derived from group IVB transition metal oxides and catalysts thus prepared
US4766247A (en) 1986-09-26 1988-08-23 Air Products And Chemicals, Inc. Color reduction of polyamines by mild catalytic hydrogenation
US5385933A (en) 1989-02-27 1995-01-31 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof
US5124351A (en) 1989-02-27 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof
MX172248B (es) 1989-12-20 1993-12-09 Univ Mexico Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5225599A (en) 1990-03-30 1993-07-06 Union Carbide Chemicals & Plastics Technology Corporation Selective production of linear triethylenetetramine and aminoethylethanolamine
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5480975A (en) 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US7816403B2 (en) 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
AU772026B2 (en) * 1998-09-25 2004-04-08 Protemix Corporation Limited Fructosamine oxidase: antagonists and inhibitors
CN1324931A (zh) 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——多铜氧化酶12和编码这种多肽的多核苷酸
RU2183961C1 (ru) 2001-08-27 2002-06-27 Новицкий Юрий Алексеевич Средство гидросульфат графито-металлический комплекс и способ лечения заболеваний кожи (их варианты)
US7365060B2 (en) 2001-11-09 2008-04-29 University Of Maryland Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
WO2003052058A2 (en) 2001-11-09 2003-06-26 University Of Maryland, College Park Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
ES2386782T3 (es) 2002-03-08 2012-08-30 Philera New Zealand Limited Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada
WO2004017957A1 (en) * 2002-08-20 2004-03-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
CN1688301A (zh) * 2002-08-20 2005-10-26 普罗特米克斯公司 药物剂型及相关的治疗用途
EP1539129A4 (en) 2002-08-20 2006-03-08 Protemix Corp Ltd DOSAGE FORMS AND RELEVANT THERAPIES
MXPA05005246A (es) 2002-11-15 2005-07-25 Ares Trading Sa Procedimiento para la purificacion de proteinas de union al factor de necrosis tumoral, usando cromatografia de afinidad de metales inmovilizados.
CN1194668C (zh) 2003-07-11 2005-03-30 马驷 纳米铜粉作为制备免疫增强药物的应用
AU2004298393A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
AU2005217623A1 (en) 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
DK1778618T3 (da) 2004-07-19 2014-03-10 Philera New Zealand Ltd Syntese af triethylentetraminer
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
DE102004056727A1 (de) 2004-11-24 2006-06-01 Cavira Biopharmaceuticals Ag Kupfer-Melphalan und Kupfer-Tegafur als Antitumormittel
WO2006104401A1 (en) 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
EP1877801A4 (en) * 2005-04-25 2009-03-18 Protemix Corp Ltd ANALYSIS AND THERAPY OF COPPER REGULATION
GB0513812D0 (en) 2005-07-05 2005-08-10 Isis Innovation Compounds for imaging and therapy
EP1948160A4 (en) 2005-11-09 2013-07-10 Protemix Corp Ltd TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
CN100436457C (zh) * 2006-12-01 2008-11-26 周成勇 N1,n8－二取代的三乙基四胺合铜(ⅱ)配合物及其制备方法
CN101322825A (zh) 2007-06-15 2008-12-17 王振军 一种治疗恶性肿瘤的药物组合物
RU2392668C1 (ru) 2008-12-15 2010-06-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ индукции антипролиферативного, цитотоксического эффекта в опухолевых клетках линейных и свежевыделенных культур
US8999294B2 (en) 2010-06-23 2015-04-07 The Board Of Regents Of The University Of Texas System Nanoparticles for use in tumor diagnosis and therapy
CN101991665B (zh) 2010-11-15 2012-05-09 张景红 治疗扩张型心肌病、股骨头坏死和肿瘤的组合物及其制备工艺
US20150072396A1 (en) 2011-03-04 2015-03-12 Life Technologies Corporation Compounds and Methods for Conjugation of Biomolecules
WO2012134822A1 (en) 2011-03-28 2012-10-04 Memorial Sloan-Kettering Cancer Center Allosteric reversible pan-caspase inhibitors
CN102274347B (zh) 2011-07-15 2013-11-06 陈迪 抗癌组合物
CN102357100A (zh) 2011-10-12 2012-02-22 沈阳药科大学 抗肿瘤联合药物
CN102614191A (zh) 2012-02-29 2012-08-01 吉林大学 硫杂杯芳烃金属配合物的合成及作为抗癌药物的用途
CN103467577B (zh) 2012-06-08 2015-07-08 四川大学华西医院 一种短肽、载铜纳米生物材料及在制备治疗下肢缺血性疾病的药物中的应用
TWI568454B (zh) 2012-08-28 2017-02-01 原創生醫股份有限公司 含金屬之複合微胞藥物載體的觸發釋放方法
JP6449537B2 (ja) 2012-12-27 2019-01-09 日本メジフィジックス株式会社 抗腫瘍剤、及び、抗腫瘍用キット
EP2948438A4 (en) 2013-01-23 2016-10-05 Univ Chicago METHODS AND COMPOSITIONS FOR INHIBITING ATOX1 AND CCS PROTEINS INVOLVED IN COPPER TRANSFER
CN103265452B (zh) 2013-05-29 2014-04-09 福州大学 一种希夫碱配体和其铜配合物及应用
CN103467497B (zh) 2013-09-03 2016-04-13 广西师范大学 以水杨醛缩牛磺酸和咪唑为配体的双配体铜配合物及其合成方法和其用途
CN103788118B (zh) 2014-02-21 2016-05-25 南开大学 单核铜配合物及其制备方法和应用
CN103951602B (zh) 2014-03-19 2016-06-15 河南理工大学 具有抗肿瘤活性的吡咯缩氨基硫脲铜、镍配合物的合成方法
CN103936772A (zh) 2014-05-05 2014-07-23 河南理工大学 一种具有抗肿瘤活性的双核铜配合物的制备方法
CN106278907B (zh) 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 一种盐酸曲恩汀化合物
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration

Also Published As

Publication number Publication date
WO2017050271A1 (en) 2017-03-30
US11033579B2 (en) 2021-06-15
EP3352743A4 (en) 2019-07-03
CA2998958C (en) 2020-12-22
EA037045B1 (ru) 2021-01-29
CA2998958A1 (en) 2017-03-30
US20210379102A1 (en) 2021-12-09
CN117338762A (zh) 2024-01-05
HK1259032A1 (zh) 2019-11-22
JP2018531931A (ja) 2018-11-01
AU2016328156A1 (en) 2018-04-12
UA123503C2 (uk) 2021-04-14
CO2018004189A2 (es) 2018-07-19
US20180296598A1 (en) 2018-10-18
CN108697669B (zh) 2023-08-15
KR20180055877A (ko) 2018-05-25
MX2018003434A (es) 2018-11-09
EP3352743A1 (en) 2018-08-01
CL2018000742A1 (es) 2018-11-09
CN108697669A (zh) 2018-10-23
ECSP18031122A (es) 2018-05-31
NZ740728A (en) 2019-07-26
BR112018005638A2 (pt) 2018-10-09
JP7041053B2 (ja) 2022-03-23
PE20181166A1 (es) 2018-07-19
AU2016328156B2 (en) 2022-03-17
WO2017049529A1 (en) 2017-03-30
IL257904A (en) 2018-05-31
IL257904B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EA201890753A1 (ru) Применение триентина для доставки меди в ишемизированную ткань
CY1123853T1 (el) Ρυθμιστες nrf2
CL2015003731A1 (es) Inhibidores de bromodominios
ZA202305280B (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
BR112017018715A2 (pt) agonista de receptor de angiotensina ii para tratar fibrose pulmonar
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
BR112018071592A8 (pt) inibidores de erbb e usos dos mesmos
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
EA201691493A1 (ru) Замещенные n-арилпиридиноны
EA202191471A1 (ru) Противовоспалительные полипептиды
EA201791716A1 (ru) Фармацевтический состав
BR112017004552A2 (pt) composições farmacêuticas
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза
EA201792093A1 (ru) 2-тиопиримидиноны
TR201722950A2 (tr) Koah tedavisinde yeni farmasötik bileşimler.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA201991135A1 (ru) Комбинированная терапия ингибиторами аргиназы
EA201991733A1 (ru) Фармацевтические композиции для комбинированной терапии
EA201992151A1 (ru) Фармацевтические композиции для комбинированной терапии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM